Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business acquisition

Telix acquires ITM Isotope Technologies Munich

Analysis based on 7 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026

Sentiment
15
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The deal reinforces the consolidation trend in radiopharmaceuticals, lifting sentiment for Telix and peers with radioisotope supply and late-stage therapeutic pipelines while pressuring competitors such as Novartis in neuroendocrine tumor therapies. Share issuance of $1.25 billion and assumed debt modestly dilute Telix equity but the acquired profitable isotope business and ITM-11 optionality support longer-term revenue and EBITDA growth expectations.

pharmaceuticals radiopharmaceuticals healthcare

Telix Pharmaceuticals agreed to acquire privately held ITM Isotope Technologies Munich in a deal valued at up to $2.35 billion, comprising $1.65 billion upfront plus up to $700 million in contingent milestone payments. The upfront consideration includes $1.25 billion paid through 105.8 million Telix shares priced at $11.841 each, released as Nasdaq-listed American Depositary Receipts after escrow periods, while Telix assumes $302 million of ITM net debt and sellers bear $96 million of management equity rollover and transaction expenses. Upon completion, existing Telix shareholders would own about 76.3% and ITM shareholders about 23.7% of the combined company. ITM, founded in 2004 and based in Munich, Germany, manufactures radioisotopes including lutetium-177, actinium-225 and terbium-161, operates two GMP manufacturing sites and distributes across more than 65 countries, with 15 years of exclusive access to Bruce Power reactors in Canada via Isogen. Its lead asset ITM-11 (lutetium-177 edotreotide) for gastro-enteropancreatic neuroendocrine tumors completed Phase 3 development, though the United States — Food and Drug Administration reportedly rejected the application over third-party manufacturing issues, with resubmission planned. ITM generated $273 million revenue in 2025 with a 40% CAGR from 2021 to 2025, and management projects combined 2026 revenue above $1.3 billion. The transaction continues radiopharmaceutical sector consolidation involving Novartis, Eli Lilly and Company, AstraZeneca, Sanofi, Bristol Myers Squibb, Curium Pharma and Lantheus Holdings. Closing is expected by the end of fiscal 2026, subject to Telix shareholder and regulatory approvals, with an extraordinary general meeting scheduled for November 2026.

45 Curium Pharma acquiring Lantheus Lantheus Holdings
25 Telix Pharmaceuticals acquired RLS
25 Aktis Oncology completed IPO
20 Eli Lilly and Company acquired radiopharmaceutical companies
20 AstraZeneca acquired radiopharmaceutical companies
20 Sanofi acquired radiopharmaceutical companies
20 Bristol Myers Squibb acquired radiopharmaceutical companies
stock
Acquirer paying up to $2.35 billion, expanding into radioisotope manufacturing and late-stage therapeutics while issuing $1.25 billion in shares and assuming $302 million net debt. The deal broadens its theranostics portfolio and vertical integration but dilutes existing holders to about 76.3%.
Importance 100.0 Sentiment 25.0
priv
Target being acquired at up to $2.35 billion, giving its shareholders about 23.7% of the combined company and access to Telix's commercial platform. Its profitable radioisotope business and ITM-11 pipeline are the core strategic assets.
Importance 95.0 Sentiment 30.0
stock
Dominant radiopharmaceutical player with Pluvicto and Lutathera faces a more vertically integrated competitor as Telix absorbs ITM's isotope supply and neuroendocrine tumor pipeline.
Importance 40.0 Sentiment -10.0
govactor
Reportedly rejected ITM-11's application over third-party manufacturing issues and approved Telix's Pixclara and Curium's Bexlutry; its approvals gate up to $250 million in milestone payments.
Importance 35.0 Sentiment 0.0
cnt
Key market where FDA approvals and Nasdaq-listed ADRs for the share consideration shape the deal's milestone structure and investor access.
Importance 25.0 Sentiment 5.0
stock
Being acquired by Curium Pharma in an $8 billion deal, a parallel consolidation move that intensifies competition for Telix's expanded radiopharmaceutical platform.
Importance 25.0 Sentiment -5.0
priv
Recently won FDA approval for Bexlutry and is closing its $8 billion purchase of Lantheus Holdings, making it a consolidating rival to the enlarged Telix.
Importance 25.0 Sentiment 5.0
priv
Its Canadian nuclear reactors provide irradiation services underpinning ITM's lutetium-177 supply through a 15-year exclusive agreement via Isogen, a key asset transferred in the deal.
Importance 20.0 Sentiment 5.0
cnt
Home market of acquirer Telix, whose ASX-listed shares and Australian base anchor the transaction's regulatory and shareholder approval process.
Importance 20.0 Sentiment 5.0
cnt
Home country of target ITM, based in Munich, whose manufacturing sites and radioisotope operations become part of the combined company.
Importance 20.0 Sentiment 5.0
curr
Currency in which the $1.65 billion upfront, $700 million milestones and ITM's $273 million revenue are denominated, with Telix reporting financials in US dollars.
Importance 20.0 Sentiment 0.0
exch
Exchange where the 105.8 million Telix shares issued as consideration will be released as American Depositary Receipts after escrow periods.
Importance 15.0 Sentiment 0.0
cnt
Location of Bruce Power reactors providing irradiation services essential to ITM's lutetium-177 production under the Isogen agreement.
Importance 15.0 Sentiment 0.0
stock
Cited among big pharma buyers of radiopharmaceutical assets from 2023 to 2025, reflecting the sector consolidation backdrop to this deal.
Importance 15.0 Sentiment 0.0
stock
Listed among recent acquirers of radiopharmaceutical companies or assets, part of the consolidation wave that frames the Telix-ITM transaction.
Importance 15.0 Sentiment 0.0
+ 6 more entities View on Dashboard
Novartis related ↔ United States
United States related ↔ Australia
United States strained ally ↔ Germany The United States considers Germany a crucial NATO ally and important trade partner, but has initiated tariffs and troop
Australia related ↔ Germany
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.